Lilly looks eastward with generics deal

Eli Lilly ($LLY) is reportedly in early talks with Turkish generics maker Mustafa Nevzat Ilac Sanayii AS, also known as MN. The talks possibly concern a partnership or investment.

A union of the two would give Lilly access to the low-cost product manufacturing, local distribution and regulatory expertise MN has in place, reports the Wall Street Journal. Turkey also serves a gateway to Asia.

MN makes generic antibiotics and would enjoy an expansive Western distribution network.

The Indianapolis drug giant recently reaped the benefits of a tie-up with Boehringer Ingelheim in a disease--rather than geographic--market deal. The collaborators are targeting diabetes and last month earned European regulatory approved for linagliptin, one of several late-stage diabetes drugs in mid- and late-stage development.

- here's the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.